Danvatirsen
- Generic Name
- Danvatirsen
- Drug Type
- Biotech
- CAS Number
- 1402357-06-5
- Unique Ingredient Identifier
- 31N550RD05
- Background
Danvatirsen is under investigation in clinical trial NCT03334617 (Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy.).
Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML
- Conditions
- AML/MDSAcute Myeloid LeukemiaMyelodysplastic Syndromes
- Interventions
- Combination Product: Danvatirsen + Venetoclax
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- Montefiore Medical Center
- Target Recruit Count
- 24
- Registration Number
- NCT05986240
- Locations
- 🇺🇸
Montefiore Medical Center, Bronx, New York, United States
🇺🇸M.D. Anderson Cancer Center, Department of Leukemia, Houston, Texas, United States
Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Flamingo Therapeutics NV
- Target Recruit Count
- 81
- Registration Number
- NCT05814666
- Locations
- 🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸University of Maryland Baltimore, Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸UT Southwestern Medical Center/Simmons Comprehensive Cancer Center, Dallas, Texas, United States
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC
- Conditions
- Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2019-01-28
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 175
- Registration Number
- NCT03819465
- Locations
- 🇹🇭
Research Site, Hat Yai, Thailand
Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)
- Conditions
- Non-hodgkin's LymphomaDiffuse Large B Cell LymphomaNHLDLBCL
- Interventions
- First Posted Date
- 2018-05-17
- Last Posted Date
- 2022-08-15
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 30
- Registration Number
- NCT03527147
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer
- Conditions
- Advanced Solid Tumours
- Interventions
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 76
- Registration Number
- NCT03421353
- Locations
- 🇺🇸
Research Site, Fairfax, Virginia, United States
Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Drug: AZD6738 (ceralasertib)Drug: AZD6738 (ceralasertib) 7 days monotherapyDrug: AZD6738 (ceralasertib) (240 mg or 160 mg)
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 527
- Registration Number
- NCT03334617
- Locations
- 🇪🇸
Research Site, Sevilla, Spain
Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer
- Conditions
- Refractory Lung CarcinomaRefractory Pancreatic CarcinomaStage II Pancreatic Cancer AJCC v8Stage III Colorectal Cancer AJCC v8Stage III Lung Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage IIIA Colorectal Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8Stage IIIB Colorectal Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8
- Interventions
- First Posted Date
- 2016-12-06
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 39
- Registration Number
- NCT02983578
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2015-09-15
- Last Posted Date
- 2019-02-27
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 32
- Registration Number
- NCT02549651
- Locations
- 🇬🇧
Research Site, Leicester, United Kingdom
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer
- Conditions
- Muscle Invasive Bladder Cancer
- Interventions
- First Posted Date
- 2015-09-11
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 117
- Registration Number
- NCT02546661
- Locations
- 🇬🇧
Research Site, Southampton, United Kingdom
Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck
- Conditions
- Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck
- Interventions
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 340
- Registration Number
- NCT02499328
- Locations
- 🇬🇧
Research Site, Taunton, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.